Exact Sciences Corp.’s fortunes are on the upswing. Sales of its Cologuard test for colorectal cancer are on the rise, its stock is hitting record highs, and the company has padded its coffers with the sale of even more stock. Its new research and development...
Watch a video that highlights Exact Sciences' innovative research and development in cancer detection....
Illumina has received US Food and Drug Administration approval for a companion diagnostic test, which it has been developing with Amgen, to run on its MiSeqDx system....
Exact Sciences today announced it is teaming up with Madison professional golfer Jerry Kelly to help drive home the importance of colorectal cancer screening....
Stratatech said this week that the first patient has been enrolled in a Phase 3 clinical trial of the cell-based regenerative skin tissue the company is developing....
The latest “Wisconsin Portfolio,” an annual report by the Wisconsin Technology Council, provides statistical evidence of what many observers of the early stage economy already suspected. There are more deals taking place in Wisconsin as more promising, high-growth companies are launched....
Exact Sciences Corp. plans to sell another 7 million to 8 million shares of common stock to expand its operations and finance product development....
Exact Sciences saw its stock price rise late Tuesday on news that the health insurer UnitedHealthcare will cover Cologuard, Exact’s stool-based DNA test for colorectal cancer, starting July 1....
Ranked sixth in the nation among universities for research and development expenditures, the University of Wisconsin-Madison is a powerful economic engine in the region and across the state....
A recent Madison Region Economic Partnership event highlighted the benefits of diversity in the workforce....